Samsung Life Public Welfare Foundation

Sk Biopharmaceuticals Co., Ltd.

Sk Holdings Co., Ltd.

Solsion Biomedical Inc.

Hyeon Cheol Gwon

So Young Lee

Sun Gwan Hwang

Sung Jin Bae

Sang Rak Choi

Jeong Woo Cho

Tae Sung Koo

Kyung Chul Cho

Hyung Suk Jang

Dong Youn Lee

Min Hee Kim

The present invention relates to a composition for preventing, treating, or alleviating ischemia-reperfusion injury, containing bile acid. According to the present invention, bile acid increases intranuclear beta-catenin levels, interferes with the opening of a mitochondria permeable transition pore (mPTP), and has excellent effects, in ischemia-reperfusion injury animal models, of alleviating tissue injury and reducing the size of infarcts, thereby being usable in the prevention, treatment, or alleviation of ischemia-reperfusion injury.

Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids

There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives

Growing community of inventors

Seoul, South Korea

Hyeon Cheol Gwon